Johannes Roesch

Johannes Roesch

Auto-generated profile, based on publicly available information

Johannes Roesch

Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Deutsches Zentrum Immuntherapie, Erlangen, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JRJ. Roesch
J. Roesch
CPC. Panje
C. Panje
FSF. Sterzing
F. Sterzing
FMF. Mantel
F. Mantel
UNU. Nestle
U. Nestle
MGM. Guckenberger
M. Guckenberger
Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of peripheral lung tumors. However, the discussion on SBRT for centrally located tumors is controversial. This study evaluated current clinical practice regarding SBRT of centrally located lung tumors, to identify common fractionation schedules and commonly accepted contraindications for SBRT. A questionnaire consisting of two parts was introduced at the annual meeting of the DEGRO working group on stereotactic radiotherapy, representing centers in Germany and Switzerland. The first part of the questionnaire covered general information about the centers, whereas the second part specifically addressed SBRT of centrally located lung tumors, using case examples of nine primary NSCLC patients. Reconstructions of a contrast enhanced CT, as well as PET-Imaging for each case were demonstrated to the participants. Twenty-six centers participated in the meeting. The majority was academic (73%), participated in interdisciplinary thoracic oncology tumorboards (88%) and offered SBRT for lung tumors (96%). Two centers questioned the indication of SBRT for central lung tumors because of lack of evidence. The majority of centers had experience in SBRT for central lung tumors (88%) and half of the centers reported more than ten cases treated during a median period of five years. Most fractionation schedules used PTV encompassing doses of 48–60 Gy in eight fractions with maximum doses of 125–150%. A clear indication for SBRT treatment was seen by more than 85% of centers in three of the nine patients in whom tumors were small and not closer than 2 cm to the main bronchus. Prior pneumonectomy or immediate adjacency to hilar/mediastinal structures were not considered as contraindications for SBRT. In cases where the tumor exceeded 4 cm in diameter or was located closer than 4 cm to the carina 50–80% of centers saw an indication for SBRT. One case, with a 7 cm tumor reaching to the carina would have been treated with SBRT only by one center. Within DEGRO working group on stereotactic radiotherapy, SBRT for small (<4 cm) early stage NSCLC is a common indication, if the minimal distance to the main bronchi is at least 2 cm. The controversy on the treatment of larger and more central tumors will hopefully be solved by ongoing prospective clinical trials.

20 October 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JRJohannes Roesch
Johannes Roesch
MOMichael Oertel
Michael Oertel
SWSimone Wegen
Simone Wegen
MTMaike Trommer
Maike Trommer
JSJulia Schleifenbaum
Julia Schleifenbaum
MHMarkus Hecht
Markus Hecht

11 September 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JRJohannes Roesch
Johannes Roesch
JCJohn B.C. Cho
John B.C. Cho
DFDaniel K. Fahim
Daniel K. Fahim
PGPeter C. Gerszten
Peter C. Gerszten
JFJohn C. Flickinger
John C. Flickinger
MGMatthias Guckenberger
Matthias Guckenberger
Stereotactic body radiotherapy (SBRT) for vertebral metastases has emerged as a promising technique, offering high rates of symptom relief and local control combined with low risk of toxicity. Nonetheless, local failure or vertebral instability may occur after spine SBRT, generating the need for subsequent surgery in the irradiated region. This study evaluated whether there is an increased incidence of surgical complications in patients previously treated with SBRT at the index level. Based upon a retrospective international database of 704 cases treated with SBRT for vertebral metastases, 30 patients treated at 6 different institutions were identified who underwent surgery in a region previously treated with SBRT. Thirty patients, median age 59 years (range 27–84 years) underwent SBRT for 32 vertebral metastases followed by surgery at the same vertebra. Median follow-up time from SBRT was 17 months. In 17 cases, conventional radiotherapy had been delivered prior to SBRT at a median dose of 30 Gy in median 10 fractions. SBRT was administered with a median prescription dose of 19.3 Gy (range 15–65 Gy) delivered in median 1 fraction (range 1–17) (median EQD2/10 = 44 Gy). The median time interval between SBRT and surgical salvage therapy was 6 months (range 1–39 months). Reasons for subsequent surgery were pain (n = 28), neurological deterioration (n = 15) or fracture of the vertebral body (n = 13). Open surgical decompression (n = 24) and/or stabilization (n = 18) were most frequently performed; Five patients (6 vertebrae) were treated without complications with vertebroplasty only. Increased fibrosis complicating the surgical procedure was explicitly stated in one surgical report. Two durotomies occurred which were closed during the operation, associated with a neurological deficit in one patient. Median blood loss was 500 ml, but five patients had a blood loss of more than 1 l during the procedure. Delayed wound healing was reported in two cases. One patient died within 30 days of the operation. In this series of surgical interventions following spine SBRT, the overall complication rate was 19%, which appears comparable to primary surgery without previous SBRT. Prior spine SBRT does not appear to significantly increase the risk of intra- and post-surgical complications.

9 November 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KKKonstantina Karava
Konstantina Karava
SEStefanie Ehrbar
Stefanie Ehrbar
Oliver RiestererOliver Riesterer
Oliver Riesterer
JRJohannes Roesch
Johannes Roesch
SGStefan Glatz
Stefan Glatz
STStephanie Tanadini-Lang
Stephanie Tanadini-Lang
Radiotherapy for pancreatic cancer has two major challenges: (I) the tumor is adjacent to several critical organs and, (II) the mobility of both, the tumor and its surrounding organs at risk (OARs). A treatment planning study simulating stereotactic body radiation therapy (SBRT) for pancreatic tumors with both the internal target volume (ITV) concept and the tumor tracking approach was performed. The two respiratory motion-management techniques were compared in terms of doses to the target volume and organs at risk. Two volumetric-modulated arc therapy (VMAT) treatment plans (5 × 5 Gy) were created for each of the 12 previously treated pancreatic cancer patients, one using the ITV concept and one the tumor tracking approach. To better evaluate the overall dose delivered to the moving tumor volume, 4D dose calculations were performed on four-dimensional computed tomography (4DCT) scans. The resulting planning target volume (PTV) size for each technique was analyzed. Target and OAR dose parameters were reported and analyzed for both 3D and 4D dose calculation. Tumor motion ranged from 1.3 to 11.2 mm. Tracking led to a reduction of PTV size (max. 39.2%) accompanied with significant better tumor coverage (p<0.05, paired Wilcoxon signed rank test) both in 3D and 4D dose calculations and improved organ at risk sparing. Especially for duodenum, stomach and liver, the mean dose was significantly reduced (p<0.05) with tracking for 3D and 4D dose calculations. By using an adaptive tumor tracking approach for respiratory-induced pancreatic motion management, a significant reduction in PTV size can be achieved, which subsequently facilitates treatment planning, and improves organ dose sparing. The dosimetric benefit of tumor tracking is organ and patient-specific.

1 August 2014
Verified
Journal Article
Open access
PDF file
JRJohannes Roesch
Johannes Roesch
NANicolaus Andratschke
Nicolaus Andratschke
MGMatthias Guckenberger
Matthias Guckenberger
SBRT in operable early stage lung cancer patients

28 May 2021
Verified
Book Chapter
Closed access
PDF file
JRJohannes Roesch
Johannes Roesch
SGStefan Glatz
Stefan Glatz
MGMatthias Guckenberger
Matthias Guckenberger
<!----> <!----> With its increasing use beginning with cranial tumors, stereotactic radiotherapy (SRT) has successively opened up a broad field of indications. In 2011, a survey among radiation oncologists in the United States showed that 39% of the physicians were using stereotactic body radiotherapy (SBRT) for the treatment of spinal tumors. Both SBRT users and nonusers were planning to increase the number of SBRT treatments (Pan et al., 2011). Likewise, a survey in six European countries reported that one-third of the centers were practicing SBRT for vertebral tumors and half of the centers considered the currently available evidence as sufficient for routine treatment outside of clinical trials (Dahele et al., 2015). New techniques and technology have opened the way to improve old and achieve new objectives of spinal irradiation. Pain relief and prevention/reduction of morbidities from bone metastases, like neurological deficits or vertebral instability, are still the main goals (Lutz et al., 2011). Furthermore, disease control in selected oligometastatic patients and delay of systemic disease progression are emerging indications. Recent developments and growing 136experience in this field have led to recommendations particularly pertaining to delineation and image-guided treatment delivery. <!----> <!---->